Description
PT-141 (Bremelanotide)
PT-141 is a synthetic peptide derived from the α-MSH (alpha-melanocyte-stimulating) hormone. It was discovered by chance while being studied as a sunless tanning agent, but volunteers reported a marked increase in sexual desire. Today, it is the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, and it is used in men with erectile dysfunction or low libido.
- Product authenticity can be verified by scanning the QR code on the packaging.
Warnings:
- Keep out of reach of children.
- Store in a cool, dry place.
Characteristics:
- 10 mg per vial
- 3 mL per vial
- Includes Bac Water
Mechanism of action
Activates MC3R and MC4R melanocortin receptors in the hypothalamus → dopamine and nitric oxide release → central desire and erection, independent of blood flow.
Activates MC3R and MC4R melanocortin receptors in the hypothalamus → dopamine and nitric oxide release → central desire and erection, independent of blood flow.
Key benefits
-
Women: increases desire, arousal, and genital sensitivity; reduces distress due to low libido in menopause or stress.
-
Men: improves erection and libido even in cases refractory to PDE-5 inhibitors (diabetes, post-prostatectomy).
-
No interaction with alcohol (unlike flibanserin).
Common adverse effects
Mild nausea (≈ 11%), facial flushing, transient headache; rarely mild hypertension.
Mild nausea (≈ 11%), facial flushing, transient headache; rarely mild hypertension.
Experimental scope
Phase II/III trials show synergy with sildenafil: greater erection rigidity and duration without increasing side effects.
Phase II/III trials show synergy with sildenafil: greater erection rigidity and duration without increasing side effects.
Current indications
-
Premenopausal women with HSDD (FDA-approved).
-
Men with psychogenic or mixed ED, or as a desire enhancer (compassionate use).
Reviews
There are no reviews yet.